DelveInsight’s, “Metastatic Renal Cell Carcinoma Pipeline Insight 2023” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Metastatic Renal Cell Carcinoma pipeline landscape. It covers the Metastatic Renal Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Renal Cell Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Metastatic Renal Cell Carcinoma Pipeline Report

• DelveInsight’s Metastatic Renal Cell Carcinoma pipeline report depicts a robust space with 40+ active players working to develop 50+ pipeline therapies for Metastatic Renal Cell Carcinoma treatment.
• The leading companies working in the Metastatic Renal Cell Carcinoma Market include AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co. Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd, and others.
• Promising Metastatic Renal Cell Carcinoma Pipeline Therapies in the various stages of development include Nivolumab, Ipilimumab, Sunitinib, Pazopanib, Tc 99m EC20, AGS-16C3F, Axitinib, and others.
• December 2023: Ipsen announced a study of Phase 2 clinical trials for Cabozantinib. The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.
• December 2023: Hoffmann-La Roche announced a study of Phase 2 clinical trials for Tobemstomig, Tiragolumab, Pembrolizumab and Axitinib. This study will evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (also known as RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib, as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).

 

Request a sample and discover the recent advances in Metastatic Renal Cell Carcinoma Treatment Drugs @ Metastatic Renal Cell Carcinoma Pipeline Outlook Report

 

In the Metastatic Renal Cell Carcinoma pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Metastatic Renal Cell Carcinoma NDA approvals (if any), and product development activities comprising the technology, Metastatic Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Metastatic Renal Cell Carcinoma Overview

Renal cell carcinoma is the most common type of kidney cancer in adults. It accounts for approximately 85% of neoplasms arising from the kidney. Renal cell carcinoma may remain clinically occult for most of its course. Only 10% of patients present with the classic triad of flank pain, hematuria, and flank mass. Patients with renal cell cancer (RCC) develop metastatic spread in approximately 33% of cases.

 

Find out more about Metastatic Renal Cell Carcinoma Therapeutics Assessment @ Metastatic Renal Cell Carcinoma Preclinical and Discovery Stage Products

 

Metastatic Renal Cell Carcinoma Emerging Drugs Profile

• Olaparib: AstraZeneca
• Atezolizumab: Genentech
• TP-1454: Sumitomo Dainippon Pharma

 

Metastatic Renal Cell Carcinoma Pipeline Therapeutics Assessment

There are approx. 40+ key companies which are developing the Metastatic Renal Cell Carcinoma therapies. The Metastatic Renal Cell Carcinoma companies which have their Metastatic Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Genentech.

 

DelveInsight’s Metastatic Renal Cell Carcinoma pipeline report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Metastatic Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

 

Metastatic Renal Cell Carcinoma Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

 

Learn more about the emerging Metastatic Renal Cell Carcinoma Pipeline Therapies @ Metastatic Renal Cell Carcinoma Clinical Trials Assessment

 

Scope of the Metastatic Renal Cell Carcinoma Pipeline Report

• Coverage- Global
• Metastatic Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Metastatic Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Metastatic Renal Cell Carcinoma Companies- AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4, Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co. Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd, and others.
• Metastatic Renal Cell Carcinoma Pipeline Therapies- Nivolumab, Ipilimumab, Sunitinib, Pazopanib, Tc 99m EC20, AGS-16C3F, Axitinib, and others.

 

Dive deep into rich insights for new drugs for Metastatic Renal Cell Carcinoma Treatment, Visit @ Metastatic Renal Cell Carcinoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Metastatic Renal Cell Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic Renal Cell Carcinoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Atezolizumab: Genentech
9. Drug profiles in the detailed report…..
10. Mid-Stage Products (Phase II)
11. Olaparib: AstraZeneca
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. TP-1454: Sumitomo Dainippon Pharma
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic Renal Cell Carcinoma Key Companies
21. Metastatic Renal Cell Carcinoma Key Products
22. Metastatic Renal Cell Carcinoma- Unmet Needs
23. Metastatic Renal Cell Carcinoma- Market Drivers and Barriers
24. Metastatic Renal Cell Carcinoma- Future Perspectives and Conclusion
25. Metastatic Renal Cell Carcinoma Analyst Views
26. Metastatic Renal Cell Carcinoma Key Companies
27. Appendix

 

For further information on the Metastatic Renal Cell Carcinoma Pipeline therapeutics, reach out to Metastatic Renal Cell Carcinoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-epithelial-defect-market